Corebridge Financial Inc. Sells 1,287 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Corebridge Financial Inc. trimmed its position in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 5.9% during the fourth quarter, HoldingsChannel reports. The firm owned 20,477 shares of the company’s stock after selling 1,287 shares during the quarter. Corebridge Financial Inc.’s holdings in SI-BONE were worth $287,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in SIBN. FMR LLC raised its stake in SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after buying an additional 1,198 shares during the period. Rhumbline Advisers increased its holdings in shares of SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock worth $808,000 after acquiring an additional 1,683 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of SI-BONE by 9.4% in the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock worth $265,000 after acquiring an additional 1,745 shares in the last quarter. Mainstream Capital Management LLC acquired a new stake in shares of SI-BONE during the fourth quarter worth about $53,000. Finally, R Squared Ltd bought a new position in shares of SI-BONE during the 4th quarter valued at about $73,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Activity at SI-BONE

In other news, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the sale, the senior vice president now owns 244,878 shares of the company’s stock, valued at approximately $3,462,574.92. This represents a 1.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Anthony J. Recupero sold 3,311 shares of the business’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total transaction of $46,850.65. Following the transaction, the insider now owns 284,555 shares in the company, valued at approximately $4,026,453.25. The trade was a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,776 shares of company stock valued at $96,644. 3.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Truist Financial restated a “buy” rating and set a $22.00 target price (up from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Needham & Company LLC increased their price objective on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE currently has a consensus rating of “Buy” and a consensus target price of $24.40.

SI-BONE Trading Down 4.8 %

NASDAQ:SIBN opened at $13.25 on Friday. The company has a market cap of $562.50 million, a P/E ratio of -14.40 and a beta of 1.02. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $19.16. The business has a 50 day moving average price of $15.74 and a two-hundred day moving average price of $14.64. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last released its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The business had revenue of $49.00 million during the quarter, compared to the consensus estimate of $48.87 million. As a group, analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.